Credit: CC0 Public Domain

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus.

In the long-term extension trial of two earlier phase 3 trials, patients continued anifrolumab 300 mg, switched from anifrolumab 150 mg to 300 mg, or were re-randomized from placebo to either anifrolumab 300 mg or continued placebo, administered every 4 weeks, with all patients also receiving standard therapy. Anifrolumab was administered as an intravenous infusion.

Treatment with anifrolumab was well tolerated and had an acceptable long-term safety profile, while sustaining reduction in disease activity and reducing or eliminating the need for steroid medications.

“Managing is challenging, due to the complexity of the disease itself, as well as from treatments like oral corticosteroids that can reduce disease activity, but also place a significant burden on patients when used in high doses long-term,” said corresponding author Hussein Al-Mossawi, MD, Ph.D., of AstraZeneca.

“These new data from the TULIP extension trial—the longest placebo-controlled clinical trial performed in lupus to date—support the benefit-risk profile of anifrolumab seen in previous trials, now over four years.”

More information:
Hussein Al-Mossawi, A Randomized, Placebo-controlled Phase 3 Extension Trial of the Long-term Safety & Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus, Arthritis & Rheumatology (2022). DOI: 10.1002/art.42392

Anifrolumab shows long-term promise in patients with lupus (2022, November 12)
retrieved 13 November 2022

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Read More